Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Advanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenACCESS Newswire has refocused around press release distribution, media monitoring, IR websites, events, and subscriptions after selling its Compliance business. The hook is improving ARR and retention; the risk is that the remaining company is still tiny, comp
OpenSEC filings, financial facts, source resources, and Goglides workspace context for Advanced Biomed Inc..
OpenGitLab reported FY2026 revenue of $955.2 million, gross profit of $834.5 million, operating loss of $70.5 million and operating cash flow of $232.9 million. The setup depends on DevSecOps adoption, platform consolidation, gross-margin durability, operating dis
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenC3.ai ended FY2026 with preliminary revenue inside guidance and a large cash and investments balance, but the latest evidence is dominated by a sharp revenue reset, weak Q3 gross margin, negative free cash flow, a 26% workforce reduction and Thomas Siebel's re
OpenSenmiao Technology is a very high risk China ride-hailing auto-services microcap. The filings show a small post-disposal operating base, continuing losses, material weaknesses, Nasdaq compliance pressure and potentially heavy dilution mechanics.
OpenAgroz has a real Malaysian CEA business and fast disclosed H1 2025 revenue growth, but AGRZ is a limited-disclosure microcap until it files FY2025 annual results, collects receivables and proves cash conversion.
OpenAllied still has HyperX Arena Las Vegas, Z-Tech mobile games, and a balance-sheet cushion, but the current thesis is about the late 10-K, Nasdaq delisting risk, reverse-split vote, Knighted settlement, and whether revenue can ever catch the cost base.
OpenAudioEye sits in a useful corner of software: websites and mobile apps keep needing accessibility testing, monitoring and remediation. The appeal is $41.2 million of ARR, about 78% GAAP gross margin and positive operating cash flow. The catch is that AEYE is s
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenAcco Group is not ACCO Brands. It is a Hong Kong and Singapore corporate-services microcap with US$4.9 million of FY2025 revenue, positive net income, an October 2025 Nasdaq IPO, and a January 2026 vote that approved a dual-class structure. The business is rea
OpenAgilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
Open